Trial Profile
A phase IIIB trial investigating 3-year treatment efficacy, tolerability and safety of Grazax in children aged 5-18 years with grass pollen induced rhinoconjunctivitis with/without controlled controlled asthma ( three consecutive pollen seasons treatment)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 May 2014
Price :
$35
*
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Grass pollen hypersensitivity; Rhinoconjunctivitis
- Focus Therapeutic Use
- Sponsors ALK-Abello
- 26 Mar 2014 According to European Clinical Trial Database, status changed from active, no longer recruiting to completed.
- 17 Jun 2011 New trial record